Sunovion Pharmaceuticals Inc. is a research-based pharmaceutical company dedicated to treating and preventing human disease through the discovery, development and commercialization of pharmaceutical products directed toward serving unmet medical needs. The company s drug development program has yielded a portfolio of pharmaceutical compounds with a focus on respiratory and central nervous system disorders. Its commercialization efforts are carried out by a United States-based nearly 1,250-person primary care and specialty sales force through co-promotion agreements and through out-licensing partnerships. Sunovion Pharmaceuticals selects development compounds with the potential to offer improvements over existing therapies with respect to efficacy, side-effect profile, dosage forms and, in some cases, the opportunity for additional indications. The focus of its discovery effort is to identify additional drug candidates that are directed toward treating respiratory and central nervous system disorders. These compounds are expected to complement Sunovion Pharmaceuticals pharmaceutical pipeline. Sunovion Pharmaceuticals is headquartered n Marlborough, Mass.